David Planchard MD, PhD
The European Commission has approved osimertinib (Tagrisso) as a frontline treatment for patients with EGFR
-mutant locally-advanced or metastatic non–small cell lung cancer (NSCLC), based on data from the phase III FLAURA trial.
T790M-positive NSCLC. Findings from the phase III AURA3 trial subsequently validated these approvals, which were based on early phase clinical trials.
Soria J-C, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer. N Engl J Med. 2018;378:113-125.
... to read the full story